Strs Ohio Has $87.43 Million Position in Danaher Co. (NYSE:DHR)

Strs Ohio trimmed its holdings in Danaher Co. (NYSE:DHR - Free Report) by 2.5% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 377,917 shares of the conglomerate's stock after selling 9,889 shares during the period. Strs Ohio owned 0.05% of Danaher worth $87,427,000 at the end of the most recent quarter.

Other hedge funds also recently made changes to their positions in the company. DHJJ Financial Advisors Ltd. acquired a new stake in shares of Danaher during the 3rd quarter valued at $25,000. BKM Wealth Management LLC bought a new stake in Danaher during the 4th quarter worth approximately $27,000. OFI Invest Asset Management bought a new stake in Danaher during the 3rd quarter worth approximately $30,000. First Capital Advisors Group LLC. purchased a new position in shares of Danaher in the 2nd quarter worth approximately $32,000. Finally, BOK Financial Private Wealth Inc. purchased a new position in shares of Danaher in the 3rd quarter worth approximately $34,000. 79.05% of the stock is owned by institutional investors and hedge funds.

Insider Buying and Selling

In other news, SVP Daniel Raskas sold 23,757 shares of the stock in a transaction dated Monday, February 26th. The shares were sold at an average price of $252.00, for a total value of $5,986,764.00. Following the completion of the transaction, the senior vice president now owns 38,102 shares in the company, valued at approximately $9,601,704. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. In related news, SVP Daniel Raskas sold 23,757 shares of the stock in a transaction dated Monday, February 26th. The shares were sold at an average price of $252.00, for a total value of $5,986,764.00. Following the sale, the senior vice president now directly owns 38,102 shares of the company's stock, valued at approximately $9,601,704. The sale was disclosed in a filing with the SEC, which is available through this hyperlink. Also, SVP Georgeann Couchara sold 2,622 shares of the firm's stock in a transaction dated Tuesday, February 13th. The stock was sold at an average price of $242.67, for a total transaction of $636,280.74. Following the sale, the senior vice president now directly owns 4,244 shares in the company, valued at $1,029,891.48. The disclosure for this sale can be found here. Insiders sold a total of 32,957 shares of company stock worth $8,265,802 in the last 90 days. Company insiders own 11.10% of the company's stock.

Danaher Trading Down 1.7 %

DHR stock traded down $4.05 during trading on Friday, reaching $239.95. 2,684,915 shares of the stock were exchanged, compared to its average volume of 2,480,293. The company has a current ratio of 1.68, a quick ratio of 1.37 and a debt-to-equity ratio of 0.31. The business has a 50 day moving average price of $249.71 and a 200-day moving average price of $229.90. Danaher Co. has a 1 year low of $182.09 and a 1 year high of $259.00. The firm has a market capitalization of $177.69 billion, a price-to-earnings ratio of 37.55, a P/E/G ratio of 3.65 and a beta of 0.83.

Danaher (NYSE:DHR - Get Free Report) last released its quarterly earnings results on Tuesday, January 30th. The conglomerate reported $2.09 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $1.91 by $0.18. Danaher had a net margin of 17.26% and a return on equity of 12.25%. The business had revenue of $6.41 billion for the quarter, compared to the consensus estimate of $6.10 billion. During the same period in the previous year, the firm earned $2.87 EPS. The business's revenue was down 10.2% on a year-over-year basis. On average, research analysts predict that Danaher Co. will post 7.62 earnings per share for the current year.

Danaher Increases Dividend

The business also recently announced a quarterly dividend, which will be paid on Friday, April 26th. Stockholders of record on Thursday, March 28th will be issued a $0.27 dividend. This is a boost from Danaher's previous quarterly dividend of $0.24. The ex-dividend date is Wednesday, March 27th. This represents a $1.08 annualized dividend and a dividend yield of 0.45%. Danaher's dividend payout ratio is presently 16.90%.

Wall Street Analysts Forecast Growth

Several research firms have issued reports on DHR. Citigroup increased their target price on Danaher from $255.00 to $280.00 and gave the stock a "buy" rating in a research report on Wednesday, January 31st. HSBC assumed coverage on shares of Danaher in a report on Monday, December 18th. They set a "hold" rating for the company. JPMorgan Chase & Co. boosted their price objective on shares of Danaher from $250.00 to $270.00 and gave the stock an "overweight" rating in a report on Wednesday, December 20th. KeyCorp boosted their target price on shares of Danaher from $260.00 to $290.00 and gave the company an "overweight" rating in a research note on Thursday, February 1st. Finally, Royal Bank of Canada boosted their target price on shares of Danaher from $254.00 to $282.00 and gave the company an "outperform" rating in a research note on Wednesday, January 31st. Seven equities research analysts have rated the stock with a hold rating and nine have issued a buy rating to the company. According to MarketBeat.com, the company has a consensus rating of "Moderate Buy" and an average price target of $267.43.

Danaher Company Profile

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.